baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Call 165 PGR 21.06.2024/ DE000VM58AX6 /

2024-05-10 8:38:35 AM	Chg.-0.13	Bid10:00:39 PM	Ask10:00:39 PM	Underlying	Strike price	Expiration date	Option type
4.76EUR	-2.66%	- Bid Size: -	- Ask Size: -	Progressive Corporat...	165.00 USD	2024-06-21	Call

GlobeNewswire 05-09 Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st ...

GlobeNewswire 05-09 Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate...

GlobeNewswire 05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Plan...

GlobeNewswire 05-07 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...

GlobeNewswire 05-06 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...

GlobeNewswire 05-04 The National Fire Sprinkler Association's Class of 2024: Honoring Fire Sprinkler Industry Greats

GlobeNewswire 05-02 PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Targ...

GlobeNewswire 05-01 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...

GlobeNewswire 05-01 Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 ...

GlobeNewswire 05-01 Opthea Announces Upcoming Presentations at the Retina World Congress 2024

GlobeNewswire 05-01 Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evalu...

GlobeNewswire 05-01 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 04-30 Progressive Announces Investor Relations Call

GlobeNewswire 04-25 Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Re...

GlobeNewswire 04-25 Opthea to Present at the OIS Retina Innovation Summit at ARVO

TeleTrader 04-25 Merck's Q1 sales rise by 9% to $15.8 billion

GlobeNewswire 04-24 Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society...

TeleTrader 04-23 Biden meets AOC amid divide on Israel policy

GlobeNewswire 04-22 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Snap One Ho...

GlobeNewswire 04-22 Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients i...

GlobeNewswire 04-19 Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Scleros...

GlobeNewswire 04-18 Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with B...

GlobeNewswire 04-18 TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple ...

GlobeNewswire 04-18 Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting...

GlobeNewswire 04-18 TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the P...

BVT Call 165 PGR 21.06.2024/ DE000VM58AX6 /

If you wish to receive reply to your feedback, please provide your email address.